Annexin Pharmaceuticals AB (ANNX) - Total Liabilities

Latest as of March 2026: Skr5.56 Million SEK ≈ $598.56K USD

Based on the latest financial reports, Annexin Pharmaceuticals AB (ANNX) has total liabilities worth Skr5.56 Million SEK (≈ $598.56K USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Annexin Pharmaceuticals AB (ANNX) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Annexin Pharmaceuticals AB - Total Liabilities Trend (2014–2025)

This chart illustrates how Annexin Pharmaceuticals AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ANNX total asset value.

Annexin Pharmaceuticals AB Competitors by Total Liabilities

The table below lists competitors of Annexin Pharmaceuticals AB ranked by their total liabilities.

Company	Country	Total Liabilities
BLB Limited NSE:BLBLIMITED	India	Rs27.20 Million
Immuron Ltd AU:IMC	Australia	AU$2.06 Million
U-BX Technology Ltd. Ordinary Shares NASDAQ:UBXG	USA	$1.37 Million
ChargePanel AB ST:CHARGE	Sweden	Skr8.62 Million
Royal Hali Iplik Tekstil Mobilya Sanayi ve Ticaret AS IS:ROYAL	Turkey	TL530.86 Million
Green Rise Capital Corp V:GRF	Canada	CA$53.62 Million
Wescan Goldfields Inc V:WGF	Canada	CA$551.65K
Presurance Holdings, Inc. NASDAQ:PRHI	USA	$259.69 Million

Liability Composition Analysis (2014–2025)

This chart breaks down Annexin Pharmaceuticals AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Annexin Pharmaceuticals AB balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	3.31	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.39	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.28	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Annexin Pharmaceuticals AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Annexin Pharmaceuticals AB (2014–2025)

The table below shows the annual total liabilities of Annexin Pharmaceuticals AB from 2014 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr5.22 Million ≈ $562.19K	-1.86%
2024-12-31	Skr5.32 Million ≈ $572.84K	-33.04%
2023-12-31	Skr7.95 Million ≈ $855.44K	+21.81%
2022-12-31	Skr6.53 Million ≈ $702.30K	+7.71%
2021-12-31	Skr6.06 Million ≈ $652.05K	+34.05%
2020-12-31	Skr4.52 Million ≈ $486.42K	-0.59%
2019-12-31	Skr4.55 Million ≈ $489.33K	-26.52%
2018-12-31	Skr6.19 Million ≈ $665.93K	-3.45%
2017-12-31	Skr6.41 Million ≈ $689.71K	-18.72%
2016-12-31	Skr7.88 Million ≈ $848.55K	+140.18%
2015-12-31	Skr3.28 Million ≈ $353.30K	+234.61%
2014-12-31	Skr981.14K ≈ $105.59K	--

About Annexin Pharmaceuticals AB

ST:ANNX Sweden Biotechnology

Market Cap

$9.14 Million

Skr84.91 Million SEK

Market Cap Rank

#27399 Global

#598 in Sweden

Share Price

Skr11.85

Change (1 day)

-5.58%

52-Week Range

Skr11.85 - Skr29.60

All Time High

Skr37.00